ATE514434T1 - Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum - Google Patents

Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum

Info

Publication number
ATE514434T1
ATE514434T1 AT05723687T AT05723687T ATE514434T1 AT E514434 T1 ATE514434 T1 AT E514434T1 AT 05723687 T AT05723687 T AT 05723687T AT 05723687 T AT05723687 T AT 05723687T AT E514434 T1 ATE514434 T1 AT E514434T1
Authority
AT
Austria
Prior art keywords
insulin
tumor cell
factor receptor
inhibitor
inhibiting tumor
Prior art date
Application number
AT05723687T
Other languages
English (en)
Inventor
Andrew Kung
Constantine Mitsiades
Nicholas Mitsiades
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE514434T1 publication Critical patent/ATE514434T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05723687T 2004-02-25 2005-02-25 Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum ATE514434T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54751604P 2004-02-25 2004-02-25
PCT/US2005/005922 WO2005082415A2 (en) 2004-02-25 2005-02-25 Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth

Publications (1)

Publication Number Publication Date
ATE514434T1 true ATE514434T1 (de) 2011-07-15

Family

ID=34910909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723687T ATE514434T1 (de) 2004-02-25 2005-02-25 Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum

Country Status (6)

Country Link
US (1) US7781393B2 (de)
EP (1) EP1737493B1 (de)
JP (1) JP2007523956A (de)
AT (1) ATE514434T1 (de)
ES (1) ES2368741T3 (de)
WO (1) WO2005082415A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
BRPI0620723A2 (pt) * 2005-12-29 2011-11-22 Alcon Res Ltd inibição de igf1r mediada por rnai para tratamento de angiogênese ocular
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
ES2444890T3 (es) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20090203718A1 (en) * 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
TW200838559A (en) * 2006-11-29 2008-10-01 Imclone Systems Inc Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
ES2543015T3 (es) * 2006-12-08 2015-08-13 The Johns Hopkins University Estrategia de quimioprevención del cáncer basada en la pérdida de la impronta de IGF2
EP2104501B1 (de) * 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Verfahren zur krebsbehandlung mit igf1r-inhibitoren
EP2559771A3 (de) * 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarker und Verfahren zur Bestimmung der Empfindlichkeit gegen Rezeptor-1-Modulatoren des vaskulären Insulinwachstumsfaktors
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
US20140086901A1 (en) * 2008-02-29 2014-03-27 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Post-Radiation Tumor Growth
EP2262494A2 (de) * 2008-02-29 2010-12-22 The Board Of Trustees Of The Leland Stanford Junior University Hemmung des tumorwachstums nach bestrahlung durch einen vaskulogenese-hemmer
US20090280112A1 (en) * 2008-05-05 2009-11-12 The Regents Of The University Of California Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
WO2010022268A2 (en) * 2008-08-20 2010-02-25 The Regents Of The University Of Colorado, A Body Corporate Markers for assessing the susceptibility of cancer to igf-1r treatment
WO2010099445A2 (en) * 2009-02-26 2010-09-02 Board Of Trustees Of Michigan State University Non-covalent inhibition of the 26s proteasome and uses thereof
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
WO2011090492A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
EP2922838B1 (de) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Feste formen von {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
EP2914629A1 (de) 2012-11-05 2015-09-09 MAB Discovery GmbH Verfahren zur herstellung multispezifischer antikörper
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
ES2923942T3 (es) 2013-11-06 2022-10-03 Us Health Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
WO2021025554A1 (en) 2019-08-02 2021-02-11 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination comprising an activator of the glucocorticoid receptor and an inhibitor of ifg-1 signaling for carcinoma treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6692742B1 (en) * 1996-06-27 2004-02-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
AU2001261474B2 (en) * 2000-05-15 2006-03-09 Celgene Corporation Compositions and methods for the treatment of cancer
WO2001089304A1 (en) 2000-05-23 2001-11-29 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
CA2456008A1 (en) 2000-08-19 2002-02-28 Axordia Limited Stem cell differentiation
MY138883A (en) 2000-08-29 2009-08-28 Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia Use of asiatic acid for treatment of cencer
WO2002029858A2 (en) 2000-09-29 2002-04-11 Infineon Technologies North America Corp. Deep trench etching method to reduce/eliminate formation of black silicon
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
CN100591355C (zh) * 2002-02-14 2010-02-24 达纳-法伯癌症研究公司 治疗过度增殖疾病的组合物及其制药用途
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia

Also Published As

Publication number Publication date
JP2007523956A (ja) 2007-08-23
EP1737493A2 (de) 2007-01-03
US7781393B2 (en) 2010-08-24
WO2005082415A2 (en) 2005-09-09
ES2368741T3 (es) 2011-11-21
EP1737493B1 (de) 2011-06-29
US20080193462A1 (en) 2008-08-14
WO2005082415A3 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
ATE514434T1 (de) Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
IL180806A0 (en) Imidazopyrazine as tyrosine kinase inhibitors
ATE508119T1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
NL1031539C2 (nl) Bicyclische [3.1.0] heteroarylamiden als type 1 glycinetransportremmers.
EA201100158A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
ZA200701137B (en) Triazolophthalazines
TNSN07264A1 (en) Organic compounds
DE602005026386D1 (de) Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon
ATE538131T1 (de) Schablonenfixierte peptidomimetika
ZA200700084B (en) 2,4-DI(aminopheyl) pyrimidines AS PKL inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
DE602005000208D1 (de) Kraftstoffzufuhrsystem
AP2326A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
DE60140366D1 (de) Piperidinverbindungen zur verwendung als ccr-3-inhibitoren
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
IL177007A0 (en) 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors
SG166100A1 (en) Novel compounds
SG148179A1 (en) Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
GB0403165D0 (en) Novel uses for proton pump inhibitors
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
ZA200801332B (en) Pentacyclic kinase inhibitors
DE602007006541D1 (de) Verwendung von wassergräsern als träger für erdbodenlose kultivierung und so gebildeter träger
TW200716132A (en) Novel chemical compounds
SG149070A1 (en) Non-nucleotide reverse transcriptase inhibitors
MX2007000364A (es) Metodos para tratar cancer usando agentes que inhiben la senalizacion de wnt16.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties